In a groundbreaking Phase II trial, the new drug Jemperli (dostarlimab-gxly) has shown remarkable efficacy in treating locally advanced rectal cancer, completely eradicating tumors in all 42 participants. This drug, targeting mismatch repair deficient (dMMR) cancers, which account for 5-10% of colorectal cancers, offers a novel treatment approach that could potentially replace the need for invasive procedures like chemotherapy and radiation. The sustained complete clinical response observed in patients after an average of 26.3 months underscores the drug’s potential for durable tumor regression. Developed by GSK, Jemperli works by enhancing the body’s immune response against cancer cells, a method that has significantly fewer side effects compared to traditional treatments. With its approval already secured for endometrial cancer treatment in combination with chemotherapy, GSK is now expanding research to evaluate the drug’s effectiveness in other types of colorectal cancers. The promising results, presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, highlight Jemperli’s potential as a transformative first-line treatment for dMMR rectal cancer, aiming to improve patients’ quality of life by avoiding the debilitating consequences of current treatment modalities.
Read more at New Atlas…
